Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference

Rhea-AI Summary

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will present a corporate overview at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 3:30 PM ET. This clinical-stage biotherapeutics company focuses on innovative treatments for cardiopulmonary and infectious diseases, including its proprietary INOpulse® nitric oxide delivery system. The presentation will be accessible through a live audio webcast on the company’s website.

WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 6^th Annual Israel Conference.

Presentation Details
Date:	Thursday, November 12, 2020
Time:	3:30 PM Eastern Time

A live audio webcast and replay of the presentations will be available in the Investors section on the Company’s website at www.bellerophon.com.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts
At W2O Group:	At LifeSci Advisors:
Julie Normart	Brian Ritchie
(559) 974-3245	(212) 915-2578
jnormart@w2ogroup.com	britchie@lifesciadvisors.com

 

FAQ

What is the date of Bellerophon Therapeutics' presentation at the H.C. Wainwright 6th Annual Israel Conference?

Bellerophon Therapeutics will present on November 12, 2020.

Who will present on behalf of Bellerophon Therapeutics at the conference?

Fabian Tenenbaum, the CEO of Bellerophon Therapeutics, will present.

What time is the Bellerophon Therapeutics presentation scheduled for?

The presentation is scheduled for 3:30 PM Eastern Time.

Where can I access the webcast of Bellerophon Therapeutics' presentation?

The webcast will be available in the Investors section of Bellerophon’s website.

What is the focus of Bellerophon Therapeutics?

Bellerophon Therapeutics focuses on developing treatments for cardiopulmonary and infectious diseases.